CellPoint Digital Appointed by Virgin Atlantic and Holidays as Payment Partner
28.3.2022 02:00:00 EEST | Business Wire | Press release
CellPoint Digital, a leading global provider of Digital Commerce and Payment Orchestration solutions, today announces a new partnership with Virgin Atlantic and Virgin Holidays.
The airline and holiday package provider will use CellPoint Digital’s full payment orchestration platform to seamlessly integrate new payment methods, new acquirers and stored card facilities, enabling reduced costs, increased acceptance rates and a better customer experience.
By orchestrating payments across regions and payment methods, CellPoint Digital’s innovative platform allows merchants to adopt a multi-acquirer payments model that opens new opportunities for growth. It also helps increase top-line revenue utilising intelligent routing, increasing authorisations, and providing system uptime transparency, and reduces the operation cost of accepting cross border payments.
News of the Virgin deal comes after a series of investments by Toscafund and Penta Capital into CellPoint Digital, which brings their total investment to more than $56M.
Yasin Demir, head of distribution and payments at Virgin Atlantic, added: “We identified CellPoint Digital as specialists in payment orchestration, providing a unique and innovated mind set towards the airline payments ecosystem. Its offering aligns perfectly with our plans to add multiple new acquirers and payment methods and we are looking forward to working with them in the coming months and beyond.”
Kristian Gjerding, CEO at CellPoint Digital, commented: “Virgin is one of the largest carriers in the UK and we are excited to be working with a brand that has such an incredible global reputation. As the project progresses, we will be collaborating closely with the Virgin payments team to ensure they get maximum benefit from our payment orchestration platform.
“By utilising our comprehensive payment orchestration platform and having access to a large payments ecosystem, we can enhance the payment process for Virgin Atlantic and Holidays while bolstering its offering with popular alternative payment methods for its customers.
Our Payment Orchestration Platform will give Virgin access to a much larger payment ecosystem and enable it to offer customers their preferred method of payment for the countries it flies to. As we emerge from the pandemic, fewer travellers are using cards to purchase tickets, with the convenience of mobile devices, e-wallet options and QR codes transforming the way they pay for airline tickets. Recent research has highlighted that 84% of travellers now pay with alternative payment methods.”
CellPoint Digital’s powerful omni-channel Payment Orchestration Platform optimises digital payment transactions, from cards or alternative payment methods, and accelerates the deployment of new payment options. Users can easily scale their own payment ecosystem across the world, unify the customer payment experience across their website, mobile apps and other channels, optimise the routing of each transaction, increase conversion rate and minimise payment costs.
To find out more, visit https://cellpointdigital.com/
ENDS
About CellPoint Digital
CellPoint Digital is a fintech leader in payment orchestration. CellPoint Digital’s main solution is a powerful omni-channel Payment Orchestration Platform that optimises digital payment transactions, from cards or alternative payment methods, and accelerates the deployment of new payment options. Merchants can easily scale their own payment ecosystem across the world, unify the customer payment experience across their website, mobile apps and other channels, optimize the routing of each transaction, increase conversion rates and minimise payment costs. Toscafund and Penta Capital have invested more than $56 million into CellPoint Digital.
CellPoint Digital has offices in Copenhagen, Dallas, Dubai, London, Miami, Pune and Singapore.
About Virgin Atlantic
Virgin Atlantic first took to the skies in 1984, instantly shaking things up and attracting plenty of attention. Since then Virgin Atlantic has become the UK’s second largest carrier, helping customers to fly and connect all around the world, with non-stop transatlantic routes including New York, Los Angeles, Hong Kong, Delhi and Johannesburg. Plus, thanks to the joint venture with Delta, Air France and KLM, over 350 cities across North America, Europe and the UK have now become accessible.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220327005040/en/
Contact information
Becky Sales
cellpointdigital@skyparlour.com
07803 204780.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
